🇧🇪 UCB.BR — UCB SA
Salud CompraPrecio actual
290,90 EUR
Máx. histórico
290,90
0 días
Caída desde máximo
En máximo
Rango 52 semanas
197,45 – 292,20
Variación hoy
+0,24%
Cierre anterior
290,20
Rango de hoy
279,10 – 291,20
Volumen hoy
260.813
Peor caída histórica
-66,30%
15/12/2006 → 27/10/2008
Recuperado en 1466 días
Volatilidad anualizada ⓘ
28,70%
- Nombre completo
- UCB SA
- Divisa
- EUR
- Mercado
- Brussels
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 9.000
- PER ⓘ
- 25,70 (puede no estar actualizado)
- Dividend yield
- 0,50% (puede no estar actualizado)
- Precio objetivo analistas
- 291,58 EUR (puede no estar actualizado)
- Primera cotización
- 04/01/2000
- Precio actualizado
- hace 1 día
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
| Fecha de pago | Importe por participación |
|---|---|
| 04/05/2026 | 1,4500 EUR |
| 25/04/2025 | 1,3900 EUR |
| 26/04/2024 | 1,3600 EUR |
| 28/04/2023 | 1,3300 EUR |
| 29/04/2022 | 1,3000 EUR |
| 30/04/2021 | 1,2700 EUR |
| 04/05/2020 | 1,2400 EUR |
| 26/04/2019 | 1,2100 EUR |
| 27/04/2018 | 1,1800 EUR |
| 28/04/2017 | 1,1500 EUR |
| 29/04/2016 | 1,1000 EUR |
| 04/05/2015 | 1,0600 EUR |
| 29/04/2014 | 1,0400 EUR |
| 02/05/2013 | 1,0200 EUR |
| 27/04/2012 | 1,0000 EUR |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 06/03/2012 | 31,90 | 32,29 | 30,71 | 30,71 | -3,28% | 4,97% | 374.665 |
| 05/03/2012 | 31,44 | 31,78 | 31,21 | 31,75 | +0,84% | 1,83% | 239.530 |
| 02/03/2012 | 29,89 | 31,78 | 29,12 | 31,48 | +6,12% | 8,90% | 562.650 |
| 01/03/2012 | 30,36 | 30,36 | 29,67 | 29,67 | -2,13% | 2,29% | 264.855 |
| 29/02/2012 | 30,80 | 30,87 | 30,17 | 30,31 | -1,33% | 2,27% | 319.306 |
| 28/02/2012 | 30,51 | 30,82 | 30,32 | 30,72 | +1,17% | 1,64% | 209.448 |
| 27/02/2012 | 30,52 | 30,64 | 30,36 | 30,37 | -0,87% | 0,93% | 125.061 |
| 24/02/2012 | 30,71 | 30,85 | 30,50 | 30,63 | -0,10% | 1,14% | 140.567 |
| 23/02/2012 | 30,72 | 30,98 | 30,56 | 30,66 | +0,00% | 1,35% | 144.451 |
| 22/02/2012 | 30,51 | 30,76 | 30,39 | 30,66 | +0,51% | 1,23% | 153.440 |
| 21/02/2012 | 30,62 | 30,70 | 30,39 | 30,51 | -0,39% | 1,01% | 133.429 |
| 20/02/2012 | 30,89 | 30,98 | 30,40 | 30,63 | -0,37% | 1,88% | 154.700 |
| 17/02/2012 | 31,26 | 31,26 | 30,66 | 30,74 | -1,00% | 1,92% | 210.771 |
| 16/02/2012 | 31,27 | 31,42 | 30,85 | 31,05 | +0,03% | 1,82% | 188.853 |
| 15/02/2012 | 31,31 | 31,60 | 30,98 | 31,04 | -0,64% | 1,98% | 202.529 |
| 14/02/2012 | 31,20 | 31,33 | 30,90 | 31,24 | +0,00% | 1,39% | 202.857 |
| 13/02/2012 | 31,05 | 31,28 | 30,91 | 31,24 | +1,13% | 1,21% | 105.765 |
| 10/02/2012 | 30,78 | 31,15 | 30,51 | 30,89 | +0,65% | 2,06% | 160.091 |
| 09/02/2012 | 30,95 | 30,97 | 30,46 | 30,69 | -0,20% | 1,63% | 173.414 |
| 08/02/2012 | 31,65 | 31,65 | 30,70 | 30,75 | -2,57% | 2,99% | 284.676 |
| 07/02/2012 | 32,00 | 32,00 | 31,49 | 31,56 | +2,47% | 1,59% | 318.393 |
| 06/02/2012 | 30,84 | 30,95 | 30,50 | 30,80 | -0,15% | 1,44% | 167.296 |
| 03/02/2012 | 30,77 | 31,01 | 30,62 | 30,85 | +0,00% | 1,28% | 143.161 |
| 02/02/2012 | 31,05 | 31,21 | 30,75 | 30,85 | -0,71% | 1,50% | 218.177 |
| 01/02/2012 | 31,20 | 31,24 | 30,88 | 31,07 | -0,08% | 1,15% | 236.716 |
| 31/01/2012 | 31,01 | 31,21 | 30,81 | 31,09 | +0,61% | 1,27% | 183.107 |
| 30/01/2012 | 31,30 | 31,45 | 30,89 | 30,90 | -1,53% | 1,81% | 233.416 |
| 27/01/2012 | 31,25 | 32,15 | 31,13 | 31,38 | +0,38% | 3,26% | 367.997 |
| 26/01/2012 | 31,02 | 31,36 | 30,70 | 31,26 | +0,82% | 2,11% | 213.644 |
| 25/01/2012 | 30,93 | 31,50 | 30,57 | 31,01 | +0,99% | 3,02% | 303.708 |